drugset / Trial / NCT07163273
Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A prospective, interventional, single-center, single-arm, open-label, phase II study for patients with metastatic pancreatic cancer. The intervention consists of monthly alternating standard chemotherapy regimens-NALIRIFOX and GnP. The hypothesis is that induction therapy with alternating NALIRIFOX and GnP has better efficacy compared to historical observation.
Timeline
- Start
- 2025-06-20
- Primary completion
- 2027-06-20
- Completion
- 2027-06-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Comparator | Irinotecan | Small molecule | 50 mg/m2 | — |
| Comparator | Leucovorin | Small molecule | — | — |
| Comparator | Oxaliplatin | Small molecule | 60 mg/m2 | — |
| Comparator | Paclitaxel | Small molecule | 125 mg/m2 | — |
| Comparator | fluorouracil | Small molecule | 2400 mg/m2 | — |